Powerful New Tools to Diagnosis Blood Cancers in Development
Scientists are using new technology to improve the diagnosis and treatment of blood cancers, which affect 1.24 million people globally.
Scientists are using new technology to improve the diagnosis and treatment of blood cancers, which affect 1.24 million people globally.
A novel PD-L1 assay advances the promise of precision medicine.
Nano-Signature Discovery Could Revolutionize Cancer Diagnosis A quick and easy test to...
Under a new grant from the National Cancer Institute, Advanced Cell Diagnostics will partner with the Cleveland Clinic to develop an ultrasensitive diagnostic test for B-cell lymphoma.
Read MoreA new collaboration plans to provide genomic profiling and information for patients that have been unsuccessful on repeated therapy for the group of cancers that include leukemias, lymphomas, and myeloproliferative and myelodysplastic diseases.
Read MoreA new study shows the MultiOmyx profile could improve disease assessment for both diseases using multiplex proteins.
Read MoreUltra-sensitive detection of minimal residual disease now available to more people with blood cancers.
Read MoreAssay can aid physicians in better risk stratification and treatment of patients with diffuse large B-cell lymphoma.
Read MoreThe test has been shown to offer sensitivity for the detection of residual cancer cells in marrow or blood.
Read MoreWith so many types of lymphoma, there’s a wide range of corresponding lab tests to detect their presence in patients. Here, CLP takes a look at testing for the most common type of lymphoma (diffuse large B-cell
Read More